Last reviewed · How we verify
GSK2340273A
GSK2340273A is a selective inhibitor of TYK2 (tyrosine kinase 2) that suppresses JAK-STAT signaling in immune cells to reduce inflammatory responses.
GSK2340273A is a selective inhibitor of TYK2 (tyrosine kinase 2) that suppresses JAK-STAT signaling in immune cells to reduce inflammatory responses. Used for Psoriasis, Psoriatic arthritis, Inflammatory bowel disease.
At a glance
| Generic name | GSK2340273A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | TYK2 inhibitor |
| Target | TYK2 (tyrosine kinase 2) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
TYK2 is a non-receptor tyrosine kinase that plays a critical role in type I and type III interferon signaling and IL-23 signaling pathways. By selectively inhibiting TYK2, GSK2340273A reduces the activation and proliferation of pathogenic T cells and other immune cells involved in autoimmune and inflammatory diseases. This selective approach aims to provide efficacy while potentially minimizing some of the broader immunosuppressive effects associated with pan-JAK inhibition.
Approved indications
- Psoriasis
- Psoriatic arthritis
- Inflammatory bowel disease
Common side effects
- Upper respiratory tract infection
- Nasopharyngitis
- Headache
- Diarrhea
Key clinical trials
- Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age (PHASE3)
- Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults (PHASE1)
- Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years (PHASE2)
- Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults (PHASE2)
- Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older (PHASE3)
- Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older (PHASE2)
- Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age (PHASE2)
- Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |